Advanced Medical Isotope (AMIC), a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, announced that a Life Sciences Discovery Fund (LSDF) Proof of Concept Grant has been awarded for which AMIC is the commercialization partner.
The award was made to Washington State University (WSU) for the proposal titled "Optimized Injectable Radiogels for High-dose Therapy of Non-resectable Solid Tumors," submitted by Principal Investigator Dr. Darrell Fisher, in the amount of $250,000. AMIC will receive a portion of the award by supplying product to WSU for the study as well as providing scientific and technical support.
AMIC plans to use the data generated during the study to support the commercialization of the Company’s brachytherapy products. Dr. Darrell Fisher serves on the AMIC Medical Advisory Board.
AMIC CEO and Chairman James C. Katzaroff stated: "We are delighted to be working with one of the nation’s top Veterinary schools, Washington State University College of Veterinary Medicine. We are appreciative to the LSDF for their recognition of the importance of the commercialization of our patented brachytherapy technologies that aim to improve lives by offering better treatment alternatives for certain cancers."
The LSDF recently announced $1.2m in Proof of Concept grants to Washington-based organizations to foster the advancement of promising health-related technologies to commercial products.
The LSDF Board of Trustees selected the awardees following review of proposals for scientific and technical merit, commercial potential, and health and economic benefits to Washington. Awards are contingent pending final Grant Agreement execution and availability of funds.
Advanced Medical Isotope Corporation is a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications.